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Analysis of Platelet-Rich Plasma Extraction
Variations in Platelet and Blood Components
Between 4 Common Commercial Kits
Jane Fitzpatrick,*†‡ FACSP, MBBS, Max K. Bulsara,§ PhD, MSc, BSc(Hons),
Paul Robert McCrory,|| PhD, FFSEM, FACSP, FRACP, MBBS,
Martin D. Richardson,{ FRACS, MBBS, MS, and Ming Hao Zheng,‡# PhD, DM, FRCPath, FRCPA
Investigation performed at the University of Western Australia,
Crawley, Western Australia, Australia
Background: Platelet-rich plasma (PRP) has been extensively used as a treatment in tissue healing in tendinopathy, muscle injury,
and osteoarthritis. However, there is variation in methods of extraction, and this produces different types of PRP.
Purpose: To determine the composition of PRP obtained from 4 commercial separation kits, which would allow assessment of
current classification systems used in cross-study comparisons.
Study Design: Controlled laboratory study.
Methods: Three normal adults each donated 181 mL of whole blood, some of which served as a control and the remainder of
which was processed through 4 PRP separation kits: GPS III (Biomet Biologics), Smart-Prep2 (Harvest Terumo), Magellan
(Arteriocyte Medical Systems), and ACP (Device Technologies). The resultant PRP was tested for platelet count, red blood cell
count, and white blood cell count, including differential in a commercial pathology laboratory. Glucose and pH measurements were
obtained from a blood gas autoanalyzer machine.
Results: Three kits taking samples from the “buffy coat layer” were found to have greater concentrations of platelets (3-6 times
baseline), while 1 kit taking samples from plasma was found to have platelet concentrations of only 1.5 times baseline. The same 3
kits produced an increased concentration of white blood cells (3-6 times baseline); these consisted of neutrophils, leukocytes, and
monocytes. This represents high concentrations of platelets and white blood cells. A small drop in pH was thought to relate to the
citrate used in the sample preparation. Interestingly, an unexpected increase in glucose concentrations, with 3 to 6 times greater
than baseline levels, was found in all samples.
Conclusion: This study reveals the variation of blood components, including platelets, red blood cells, leukocytes, pH, and glucose in PRP extractions. The high concentrations of cells are important, as the white blood cell count in PRP samples has frequently been ignored, being considered insignificant. The lack of standardization of PRP preparation for clinical use has
contributed at least in part to the varying clinical efficacy in PRP use.
Clinical Relevance: The variation of platelet and other blood component concentrations between commercial PRP kits may affect
clinical treatment outcomes. There is a need for standardization of PRP for clinical use.
Keywords: platelet-rich plasma; PRP; leukocyte; osteoarthritis; tendinopathy

Platelet-rich plasma (PRP) is defined as a platelet-rich
concentrate with higher-than-baseline levels of platelets
when compared with whole blood. PRP is increasingly used
in prospective clinical studies to improve tissue healing,
particularly with regard to tendinitis.5,7,13,21,22,30,33,36 A
small number of randomized controlled trials have shown
the positive benefit of PRP in tendinopathy.13,22,25,33 It has

been hypothesized that this is due to platelet-derived
growth factor (PDGF), transforming growth factor beta
(TGF-b), vascular endothelial growth factor (VEGF),
insulin-like growth factor 1 (IGF-1), and hepatocyte growth
factor (HGF), which are released from the alpha granules
during in vivo activation of platelets3,5,6,9,10,12,26,41 or subsequently produced by the cellular matrix of the tendon.
DeLong et al14 considered that PRP preparations can be
divided into 2 forms: 1 plasma based, the other based on
buffy coat preparations. Plasma-based preparations aim to
capture platelets from the plasma after centrifugation and
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TABLE 1
Commercially Available Kits for the Production of Platelet Productsa
Device Name

Company

Name of Product

Comments

GPS III
SmartPrep2
Magellan
Angel
CS
ACP
PRFM Fibrinet System
PRF and Vivostat
BMAC
Cell saver–based systems Electa,
Haemonetics, CATS, BRAT
Caption

Biomet
Harvest
Arteriocyte Medical
Sorin
Genesis
Arthrex
Cascade
Choukroun’s
DePuy
Several

Platelet-rich plasma
Platelet-rich plasma
Platelet-rich plasma
Platelet-rich plasma
Platelet-rich plasma
Autologous conditioned plasma
Platelet-rich fibrin
Platelet-rich fibrin
Platelet-rich plasma and stem cells
Pure platelets

Tested
Tested
Tested
Not available for testing
Not available for testing
Tested
Not tested, fibrin membrane
Not tested, fibrin membrane
Not tested, bone marrow
Not tested, volume required >200 mL

Not yet marketed

Pure platelets

Not tested, not available

Total

12 companies

4 tested

a

Table derived from Engebretson et al.16

exclude red and white blood cells. Generally these kits produce smaller increases in platelets than the kits that take
platelets from both the plasma and the more cellular ‘‘buffy
coat.’’8,9,18
There has been some discussion about whether the efficacy of the PRP is affected by the inclusion of the white
blood cells.2,27 Moojen et al31 considered that there may
be positive effects from the white blood cells acting as antimicrobial agents. Other authors have suggested that the
platelets themselves may already have this property.38
There may also be negative effects from these white blood
cells in causing further inflammation, leading to fibrosis, or
from the release of catabolic cytokines.2,32 This effect may
be more prevalent with neutrophils than other white blood
cells.2 Recent meta-analyses of PRP in tendinopathy identified that leukocyte-rich PRP had a strongly positive outcome in the treatment of tendinopathies.19,34
There has also been discussion about whether the pH of
the resultant PRP will affect platelet function,39 and thus
whether the PRP produced should be ‘‘buffered.’’
Because it is likely to be important in the management of
different conditions to have certain types of PRP used,15 all
commercial kits should be validated for cell and PRP type,
but this has not always been the case. The purpose of this
study was to validate all kits available in Australia for their
composition of platelet, red and white blood cell counts, pH,
and glucose levels using a single-donor model. A recommendation could then be made as to which PRP kits/types are

associated with the best results in the treatment of different musculoskeletal conditions such as tendinopathy and
osteoarthritis.

METHODS
Three healthy adult human subjects were recruited and consented for this trial (2 women, 1 man; age range, 25-35 years).

Description of Common Commercial Kits
A review of all kits was undertaken as shown in Table 1
based on the International Olympic Committee (IOC) consensus paper on the use of PRP in sports medicine.16 It was
decided that only kits producing PRP, autologous conditioned plasma, or pure platelets would be assessed. Only
kits producing PRP from whole blood for use in musculoskeletal conditions such as tendinitis, muscle injuries, or
osteoarthritis were selected. Kits were excluded if they produced platelet-rich fibrin or bone marrow samples. Thus, 8
potential kits were available for testing.
Cell saver–based pure platelet systems requiring a minimum sample of 200 mL of whole blood for processing24
were not deemed appropriate to study, as this large sample
was regarded as impractical for office use. The Caption
pure platelet kit was not commercially available at the time
of testing, and therefore, 6 potential kits were available for

*Address correspondence to Jane Fitzpatrick, FACSP, MBBS, School of Surgery, The University of Western Australia, 35 Stirling Highway, Crawley,
Western Australia 6009, Australia (email: jane.fitzpatrick@research.uwa.edu.au).
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supplied by the manufacturers as follows: GPS III (Biomet Biologics), Smart-Prep2 (Harvest Terumo), Magellan (Arteriocyte Medical Systems), and ACP
(Device Technologies).
Ethical approval for this study was waived by the University of Western Australia Human Research Ethics Committee (RA/4/1/6209).
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TABLE 2
Preparation of PRP Samplesa
System
GPS III
SmartPrep2
Magellan
ACP

Blood Volume, mL

Anticoagulant Volume, mL

52
52
52
15

ACD-A
ACD-A
ACD-A
ACD-A

Centrifugal Force, g-force

Centrifuge Time, min

Volume Produced, mL

1100
1250/1050
1200
1500

15
14
17
5

6-7
6-7
6-7
6-7

8
8
8
2

a

ACD-A, anticoagulant citrate dextrose solution A; PRP, platelet-rich plasma.

TABLE 3
Cellular Dataa
Kit

Cell Type

Mean, 109/L

SD, 109/L

Median, 109/L

Min, 109/L

Max, 109/L

Control

Platelets
WBC
RBC
Platelets
WBC
RBC
Platelets
WBC
RBC
Platelets
WBC
RBC
Platelets
WBC
RBC

269
8.73
4.7
412
1.3
0.0333
964
35.8
1.03
1224
24.7
1.43
1266
31.4
1.03

106
3.75
0.436
140
0.781
0.0577
551
10.8
0.289
560
8.69
0.306
831
9.4
0.153

290
8.9
4.5
424
7.7
0
760
41.8
1.2
1262
26.1
1.5
1153
35.2
1.0

154
4.9
4.4
266
0.4
0
544
23.3
0.7
646
15.4
1.1
497
20.7
0.9

362
12.4
5.2
546
1.8
0.1
1588
42.3
1.2
1764
32.6
1.7
2148
38.3
1.2

ACP

GPS

SmartPrep

Magellan

a

RBC, red blood cell count; WBC, total white blood cell count.

study. Of these, only 4 were commercially available in Australia at the time of testing: GPS III (Biomet Biologics),
SmartPrep2 (Terumo Harvest), Magellan (Arteriocyte
Medical Systems), and ACP (Device Technologies,
Arthrex). All companies agreed for their kits to be used in
the trial and provided the kits.

Sample Collection and Processing
All samples were collected from the subjects by the
senior author (J.F.) and were processed immediately. A
total of 181 mL of blood was drawn from each subject: 5
mL was used for the control sample, 52 mL for each
of the PRP-based kits (GPS III, SmartPrep2, and
Magellan), and 15 mL for the ACP kit. The samples
were processed according to the manufacturers’ instructions to produce 6 to 7 mL of finished product, as shown
in Table 2.
The samples were then processed: 1.5 mL from the PRP
samples and the control blood were put into a tube for analysis on a blood gas testing machine (ABL800 Flex; Radiometer), generating results for pH, Kþ, Naþ, Cl–, glucose, and
lactate. The remaining control blood and PRP samples were
placed into a collection tube for analysis on a Coulter LH
250 automated analyzer (Beckman Coulter Inc) within
30 minutes of collection to measure full blood count and
white blood cell count with differential.

Classification of the PRP Produced
The results from the analysis were assessed based on the
PAW (platelet, activation, white blood cells)15 and the Mishra sports medicine PRP classification29 systems. The PAW
system classifies PRP based on platelet numbers, the manner in which activation occurs, and the presence or absence
of white blood cells. The Mishra sports medicine PRP classification system is based on platelet concentration, the
presence or absence of white blood cells, and whether the
PRP has been activated with exogenous thrombin or calcium chloride.

Statistical Analysis
All statistical analyses were performed using STATA version 13 (Stata Corp). All variables had a calculated mean
and standard deviation. Each subject was used as their own
control, and thus, change from mean was relative to their
own control result.

RESULTS
Comparison of Cellular Components
We first compared the cellular components of platelets, leukocytes, and red blood cells between these 4 kits using
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Figure 1. Platelet counts by kit type.
standard methods on 3 human subjects. A summary of data
is presented in Table 3. The values for total platelet count
as well as red and white blood cell counts are presented
compared with controls.
Platelets. An increase in platelet production was demonstrated compared with baseline in all kits (Figure 1).
The ACP kit produced a 1 to 1.7 times baseline level of
platelets (412  109/L), which is consistent with the literature for this kit and open-tube single- or double-spin systems.4,8,37,41 The Magellan (1266  109/L), GPS (964  109/L),
and SmartPrep (1224  109/L) kits produce 3 and 6 times
baseline platelet concentrations, consistent with previous
data.8,9,17,18,23,24
Red Blood Cells. All kits significantly reduced red blood
cell counts compared with controls, as seen in Figure 2. The
ACP kit virtually eliminated red blood cells. The GPS,
SmartPrep, and Magellan kits reduced the red blood cells
by 3 to 6 times baseline levels.
White Blood Cells. White blood cell counts are of great
importance. Compared with controls (white blood cell
count, 8.73  109/L), the only kit to reduce the white
blood cell count was the plasma system (ACP) (1.3 
109/L), which reduced the white blood cell count by 5 to
22 times, almost eliminating the white blood cells. The
GPS III (35.8  109/L), SmartPrep2 (24.7  109/L), and
Magellan (31.4  109/L) kits actively concentrated white
blood cells 3 to 5 times baseline levels (Figure 3). This is
consistent with the results found by Carmona et al.7
Similar increases across all 3 kits were demonstrated.
Our results showed much higher levels of white blood
cell concentration than have been indicated by others.7,8
When the white blood cell count is broken into a differential white blood cell count, the majority of cells are neutrophils and lymphocytes (Table 4 and Figure 4). Compared
with controls (5.5  109/L), the GPS and Magellan kits
contained greater mean neutrophil counts (15.4 and 15.1
 109/L, respectively). The SmartPrep kit had a lower mean
neutrophil count (6.47  109/L), and the ACP kit had a
negligible mean neutrophil count (0.4  109/L). Compared
with controls (2.37  109/L), the mean lymphocyte counts of
the GPS (15.9  109/L), SmartPrep (14.0  109/L), and
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Figure 2. Red blood cell counts by kit type.

Figure 3. Total white blood cell counts by kit type.
Magellan (12.5  109/L) were higher but similar across kits.
The ACP kit had negligible lymphocytes (0.7  109/L). The
increase in total white blood cell count was similar across
the 3 buffy coat layer kits (GPS, SmartPrep, and Magellan).
However, the relative increase in neutrophils was much
greater for the GPS and the Magellan kits.

Comparison of Chemical Composition
PRP from the kits was assessed for glucose and pH using
the Radiometer ABL800 Flex. The data for pH and glucose
are shown in Table 5 and Figures 5 and 6.
Compared with the glucose control of 4.2 mmol/L, all
PRP produced contained a high level of glucose ranging
from 15.8 to 23.6 mmol/L. This reflects an increase in
glucose of 4 to 6 times baseline.
The mean pH of the controls was 7.1. The mean pH of the
PRP produced ranged from 6.59 (SmartPrep) to 7.05 (GPS).
The lower pH in the kit samples is related to the use of the
anticoagulant citrate dextrose solution–formula A (ACD-A)
anticoagulant. The amount of ACD-A used was the same
ratio for all kits by volume.

The Orthopaedic Journal of Sports Medicine
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TABLE 4
White Blood Cell Differential Countsa
Mean ± SD, 109/L

Kit
Control
WBC
Neutrophils
Lymphocytes
Monocytes
ACP
WBC
Neutrophils
Lymphocytes
Monocytes
GPS
WBC
Neutrophils
Lymphocytes
Monocytes
Smart Prep
WBC
Neutrophils
Lymphocytes
Monocytes
Magellan
WBC
Neutrophils
Lymphocytes
Monocytes

Median (Range), 109/L

8.73 ±
5.5 ±
2.37 ±
0.6 ±

3.75
2.91
0.85
0.173

8.9
5.3
2.4
0.5

(4.9-12.4)
(2.7-8.5)
(1.5-3.2)
(0.5-0.8)

1.3 ±
0.4 ±
0.7 ±
0.167 ±

0.781
0.265
0.436
0.115

1.7
0.5
0.9
0.1

(0.4-1.8)
(0.1-0.6)
(0.2-1.0)
(0.1-0.3)

35.8 ±
15.4 ±
15.9 ±
3.8 ±

10.8
5.05
7.73
1.1

41.8
14
14.6
3.8

(23.3-42.3)
(11.2-21)
(8.9-24.2)
(2.7-4.9)

24.7 ±
6.47 ±
14 ±
3.57 ±

8.69
1.86
6.36
1

26.1
7
13
3.5

(15.4-32.6)
(4.4-8)
(8.2-20.8)
(2.6-4.6)

31.4 ±
15.1 ±
12.5 ±
3.27 ±

9.4
3.93
5.72
1.03

35.2
16.6
12
3

(20.7-38.3)
(10.6-18)
(7.1-18.5)
(2.4-4.4)

a

WBC, total white blood cell count.

Figure 4. Neutrophil and lymphocyte counts by kit type.

DISCUSSION
There are various kits available for the separation of PRP
in clinical practice. As a specific ‘‘dose’’ of platelets may be
required to achieve a clinical effect, it is important to identify the kits that produce different doses.15 Using a singledonor protocol, we have analyzed the blood components of 4
of the most common commercial kits available to medical
practitioners in Australia. We have shown an increase in
platelets from baseline in all the kits with large variations.
This was found to be 1 to 1.5 for plasma-type kits (ACP) and
between 3 and 6 times for buffy coat layer kits (GPS III,
Magellan, SmartPrep2). This confirms the work of Castillo
et al,9 who similarly compared 3 kits (Magellan, Cascade,
and GPS). In addition, there is variation in the numbers of
neutrophils, leukocytes, and monocytes between the kits.
The plasma system (ACP) reduced the white blood cell
count by 5 to 22 times, almost eliminating the white blood
cells. The buffy coat kits (GPS III, SmartPrep2, and Magellan) actively concentrated white blood cells 3 to 5 times
baseline. The increase in total white blood cell count was
similar across the 3 buffy coat layer kits (GPS, SmartPrep,
and Magellan). However, the relative increase in neutrophils was much greater for the GPS and Magellan kits.
A small reduction in pH was thought to relate to the
citrate used in the sample preparation. This reduction is
not thought to be of clinical significance. Based on the small
drop in pH, it does not seem necessary to buffer the PRP
unless this change in pH can be shown to negatively impact
the production of growth factors.

TABLE 5
pH and Glucose Data
Kit
Control
pH
Glucose
ACP
pH
Glucose
GPS
pH
Glucose
Smart Prep
pH
Glucose
Magellan
pH
Glucose

Mean ± SD, mmol/L

Median (Range), mmol/L

7.1 ± 0.28
4.2 ± 0.529

7.12 (7.07-7.12)
4.4 (3.6-4.6)

6.87 ± 0.256
18.5 ± 2.73

6.99 (6.57-7.04)
17.7 (16.2-21.5)

7.05 ± 0.02
15.8 ± 1.07

7.05 (7.03-7.07)
15.2 (15.1-17.0)

6.59 ± 0.329
23.6 ± 1.36

6.61 (6.55-6.61)
23.8 (22.2-24.9)

6.66 ± 0.102
22.3 ± 0.907

6.69 (6.54-6.74)
22.7 (21.3-23.0)

No studies have reported the level of glucose in PRP
produced previously. One of the surprising findings in this
study was the significant increases in glucose concentration of 4 to 6 times baseline in all kits. This has not been
previously reported as a significant variable, and the clinical significance of this factor is unknown. It is of interest
that glucose solutions at concentrations between 12% and
20% have been used in prolotherapy injections with
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Figure 7. Platelet-rich plasma in GPS kit after centrifugation.
Figure 5. pH by kit type.

Figure 6. Glucose by kit type.
varying results.1,11,20 It is likely this is derived from the
use of the ACD-A and is thus related to the preparation
technique consistent to all kits. If one takes 5 mL of a 10%
glucose solution (2.8-mmol solution) for injection, this
would contain 0.5 g of glucose. If we take 5 mL of PRP
produced in any of the studied kits at 20 mmol/L (70%
glucose solution), this would give us 3 g of glucose. In
simple terms, our PRP samples are producing a 6-times
glucose concentration compared with glucose solutions
used in prolotherapy. This may be important as part of the
factors producing a clinical response.
Essentially there are 2 main types of PRP preparation
methods. After centrifugation, there are 3 key layers, as
shown in Figure 7. Plasma-based systems take product
from the yellow relatively acellular plasma layer. These
systems aim to exclude red and white blood cells from the
preparation and to collect as many platelets from the
remaining ‘‘plasma’’ layer as possible. As many of the platelets are in the buffy coat layer, the resultant product is low
in red and white blood cells and has only a 1.5 to 1.7 times
baseline level of platelets. This is well demonstrated by the
results from the ACP kit in our study. The second type of
PRP product is made from the buffy coat floating above the

red blood cell layer. Levels of platelets at 3 to 6 times baseline levels are expected as the product is coming from a
more platelet-dense environment.6,9 Again, this is confirmed
by our testing, with the GPS III, Magellan, and SmartPrep2
kits having much higher platelet concentrations.
In producing PRP, all kits aim to reduce the red blood cell
count6,9,12 and increase the collection of platelets. Some
white blood cells are captured at the same time.6,9 Due to
the addition of citrate to the blood being collected, there is
likely to be a drop in pH of the sample produced. This is the
first paper to identify how other variables like lactate or
glucose are changed by this process. Generally, in most
literature review papers, the white blood cell count is
ignored or regarded as negligible. We feel that these aspects
of PRP systems should be more highly noted in future literature reports as the concentration of white blood cells is
as great as that of the platelets and there is glucose present
in the end product.
Studies by others have also shown variation of platelet
levels, growth factor and cytokine levels,32 and total white
blood cell counts across PRP preparation methods.8,9,17,18,24,27,37,40,41 However, the most important finding in our study is that the white blood cell counts are
significantly more concentrated than previously thought.
The ACP kit was the only one in our series that reduced
the white blood cell count by a factor of about 9. This may be
an important point of difference if the white blood cells are
not beneficial. The other 3 kits (GPS III, Magellan, SmartPrep2) concentrated the white blood cell count by 3 to 5
times, a similar increase to platelet concentration. Thus,
these white blood cells are not contaminants as their levels
are as high as the primary ingredient: platelets. Their
levels may be regarded as potentially clinically significant.
Furthermore, we assessed the white blood cell differential
count and found that the cellular concentration of white
blood cells was up to 40% neutrophils and lymphocytes each
and a further 10% made up of monocytes. The remainder of
the cells were basophils and eosinophils in small quantities.
An increase in the growth factor VEGF would be expected
as the number of lymphocytes increases. These lymphocytes may play an important role in further enhancing the
tissue repair processes, but they may also lead to increased
local inflammation.
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TABLE 6
PRP kits by PAW and Mishra (Sports Medicine) Classificationsa
PAW Classification
Kit
ACP
Magellan
GPS III
SmartPrep2

Mishra Classification

Platelets

WBC

Neutrophils

Resultb

Activation (PAW/Mishra)

WBC

Platelets

P2
P4
P3
P3

B
A
A
A

b
a
a
a

P2Bb
P4Aa
P3Aa
P3Aa

N/A
N/A
N/A
N/A

Minimal
Increased
Increased
Increased

<5
<5
<5
<5

Resultc
3B
1B
1B
1B

a

N/A, not applicable; WBC, total white blood cell count.
PAW classification: platelet counts: P2 ¼ baseline to 750,000; P3 ¼ 750,000-1,250,000; P4 ¼ >1,250,000. Total WCC: A ¼ above baseline,
B ¼ below or equal to baseline. Neutrophil count: a ¼ above baseline, b ¼ below baseline.
c
Mishra classification: type 1B ¼ increased WCC, no activation, platelet count <5 times baseline; type 3B ¼ minimal WCC, no activation,
platelet count <5 times baseline.
b

White blood cells may contribute to the modulation of
inflammatory and platelet activation, thereby acting to
potentiate the tissue repair mechanism. It is possible that
the white blood cells may confer an advantage to the
patient in reducing the chance of infection or modulating
the inflammatory response.31,35 This may be an important
consideration in those clinical settings where the patient is
at greater risk, such as with intra-articular procedures or at
the time of surgery. Furthermore, Zimmermann et al41
found that the increased white blood cell count was responsible for between one-third and one-half of the variation on
growth factors found in their samples. They found a positive
correlation between the white blood cell count and VEGF
(known to come from the white blood cells) and PDGF.
On the other hand, others have shown that white blood
cells appear to have a deleterious effect on the tissue,27
resulting in increased inflammation and further scarring.
These negative effects are largely due to neutrophils and
include the release of oxygen-free radicals, catabolic cytokines, matrix metalloproteinases (MMPs), and interleukin
B, which degrade tissue.14
A recent meta-analysis of the effectiveness of PRP in
tendinopathy has shown that leukocyte-rich PRP (LR-PRP)
is the most effective in the treatment of tendinopathy.19
This study allows us to recommend PRP produced by the
GPS III, SmartPrep2, and Magellan kits in the treatment of
tendinopathy. By contrast, 2 recent reviews of the effectiveness of PRP in osteoarthritis have shown that leukocytepoor PRP (LP-PRP) may be more effective.28,34
One of the surprising new findings in this study was the
significant increases in glucose concentration of 4 to 6 times
baseline in all kits. This has not been previously reported as
a significant variable, and the clinical significance of this
factor is unknown. It is of interest that glucose solutions at
concentrations of between 12% and 20% have been used in
prolotherapy injections with varying results.1,11,20 The clinical significance of this remains uncertain. This was
thought to be important as prolotherapy with glucose has
been used in the treatment of musculoskeletal injuries.
Kit validation studies help to classify kits into those
deemed similar enough to allow results from papers using
kits to be compared. Some kit classification systems have
been proposed in the past.15,29 Table 6 shows the PRP kits

classified according to both the PAW and Mishra classification systems. The classification proposed by Mishra et al29
allows for platelet concentrations >5 or <5 times baseline.
We found 3 to 6 times baseline values in the buffy coat kits
and 1.5 in the plasma kits. This classification system with a
cutoff of ±5 times concentration does not fit for either buffy
coat or plasma system results from our study. The white
blood cells are recorded only as present or absent, and there
is no accounting for the level of white blood cells. The PAW
classification system proposed by DeLong et al15 is appropriate for the classification of platelets, classifying our
tested kits into 3 different groups, but it simply classifies
the white blood cells as absent or present. Given the high
concentration of white blood cells found in our laboratory
analysis, this classification system does not adequately
account for the high numbers of white blood cells, including
both neutrophils and lymphocytes found in the PRP preparations studied. If these cells are found to be significant
for efficacy, a further breakdown of types of PRP to adequately include white blood cells will be needed. Kits classified in the same class would then be able to have their
results compared as a group when meta-analysis or comparison studies are being undertaken.

CONCLUSION
This study identifies the large variations in composition and
concentration of platelets, white blood cell counts, and the
differential count of neutrophils and lymphocytes as well as
the presence of high levels of glucose between 4 commercial
PRP kits. The clinical significance of this is that these variations must be taken into account when assessing the results
of clinical trials and in the choice of preparation by practitioners. This study highlights the need for standardization of
platelet-rich plasma extraction for clinical use.
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